Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer

Bredemeier,Maren; Kasimir‑Bauer,Sabine; Kolberg,Hans‑Christian; Herold,Thomas; Synoracki,Sarah; Hauch,Siegfried; Edimiris,Philippos; Bankfalvi,Agnes; Tewes,Mitra; Kimmig,Rainer; Aktas,Bahriye

doi:10.3892/mmr.2017.6415

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer

Authors:
- Maren Bredemeier
- Sabine Kasimir‑Bauer
- Hans‑Christian Kolberg
- Thomas Herold
- Sarah Synoracki
- Siegfried Hauch
- Philippos Edimiris
- Agnes Bankfalvi
- Mitra Tewes
- Rainer Kimmig
- Bahriye Aktas
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg‑Essen, D‑45122 Essen, Germany, Department of Gynecology and Obstetrics, Marienhospital Bottrop, D‑46236 Bottrop, Germany, Institute of Pathology, University Hospital Essen, University of Duisburg‑Essen, D‑45122 Essen, Germany, Qiagen Hannover GmbH, D‑30853 Langenhagen, Germany, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg‑Essen, D‑45122 Essen, Germany
Published online on: March 30, 2017 https://doi.org/10.3892/mmr.2017.6415
Pages: 2957-2968
Copyright: © Bredemeier et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the phosphatidylinositol 3-kinase (PI3KCA)-AKT serine/threonine kinase (AKT) pathway in circulating tumor cells (CTCs) and corresponding cancerous tissues. Stemness‑like circulating tumor cells (slCTCs) and CTCs in epithelial-mesenchymal transition (EMT) have been implicated as the active source of metastatic spread in breast cancer (BC). In this regard, the PI3KCA‑AKT signaling pathway was demonstrated to be implicated in and to be frequently mutated in BC. The present study compared this pathway in slCTCs/CTCs in EMT and the corresponding tumor tissues of 90 metastatic BC patients (pts). slCTCs and CTCs in EMT were isolated using the AdnaTest EMT-1/StemCell for the detection of aldehyde dehydrogenase 1 family member A1 (ALDH1) (singleplex PCR) and PI3KCA, AKT2 and twist family bHLH transcription factor 1 (multiplex PCR). Tumor tissue was investigated for PI3KCA hotspot mutations using Sanger sequencing of genomic DNA from micro‑dissected formalin‑fixed paraffin‑embedded tissue, and for the expression of ALDH1 and phosphorylated AKT (pAKT), and phosphatase and tensin homolog (PTEN) loss, by immunohistochemistry. slCTCs were identified in 23% of pts (21/90 pts) and CTCs in EMT in 56% (50/90 pts) of pts. pAKT and ALDH1 positivity in tumor tissue was identified in 47 and 9% of cases, respectively, and a PTEN loss was observed in 18% of pts. A significant association was detected between pAKT expression in cancerous tissue and AKT2 expression in CTCs (P=0.037). PI3KCA mutations were detected in 32% of pts, most frequently on exons 21 (55%) and 10 (45%). Pts with PI3KCA mutations in tumor tissue had a significantly longer overall survival than pts with wild-type PI3KCA expression (P=0.007). Similar results were obtained for pts with aberrant PI3KCA signaling in CTCs and/or aberrant signaling in cancerous tissue (P=0.009). Therapy‑resistant CTCs, potentially derived from the primary tumor or metastatic tissue, may be eliminated with specific PI3K pathway inhibitors, alone or in combination, to improve the prognosis of metastatic BC pts.

View Figures

View References

1	Foroni C, Broggini M, Generali D and Damia G: Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev. 38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
2	McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW and Saunders CM: Clinical implications of circulating tumor cells of breast cancer patients: Role of epithelial-mesenchymal plasticity. Front. Oncol. 5:422015.
3	Wu Y, Sarkissyan M and Vadgama JV: Epithelial-mesenchymal transition and breast cancer. J Clin Med. 5:E132016. View Article : Google Scholar : PubMed/NCBI
4	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
5	Dirican E, Akkiprik M and Özer A: Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. Tumour Biol. 37:7033–7045. 2016. View Article : Google Scholar : PubMed/NCBI
6	Thorpe LM, Yuzugullu H and Zhao JJ: PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI
7	Mayer IA and Arteaga CL: The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 67:11–28. 2016. View Article : Google Scholar : PubMed/NCBI
8	Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M and Noguchi S: Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 13:408–814. 2007. View Article : Google Scholar : PubMed/NCBI
9	Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L and Stål O: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 13:3577–3584. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W and Moynahan ME: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 15:5049–5059. 2009. View Article : Google Scholar : PubMed/NCBI
11	Li SY, Rong M, Grieu F and Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 96:91–95. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69:4116–4124. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Fourme E, Lidereau R and Bièche I: PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res. 14:R282012. View Article : Google Scholar : PubMed/NCBI
14	Lee JJ, Loh K and Yap YS: PI3K/AKT/mTOR inhibitors in breast cancer. Cancer Biol Med. 12:342–354. 2015.PubMed/NCBI
15	Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
16	André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, et al: Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 34:2115–2124. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, et al: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 16:816–829. 2015. View Article : Google Scholar : PubMed/NCBI
18	André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, et al: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15:580–591. 2014. View Article : Google Scholar : PubMed/NCBI
19	Baselga J, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, et al: The phase III BELLE-2 trial. San Antonio breast cancer symposium. Abstract S6-01, Presented December. 2015.
20	Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R462009. View Article : Google Scholar : PubMed/NCBI
21	Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D and Georgoulias V: Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288:99–106. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V and Agelaki S: Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 13:R592011. View Article : Google Scholar : PubMed/NCBI
23	Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R and Fehm T: Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14:R152012. View Article : Google Scholar : PubMed/NCBI
24	Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V and Agelaki S: Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer. 14:6512014. View Article : Google Scholar : PubMed/NCBI
25	Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E and Fehm T: Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int. 2014:4157212014. View Article : Google Scholar : PubMed/NCBI
26	Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, et al: Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 11:2526–2534. 2012. View Article : Google Scholar : PubMed/NCBI
27	Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV and Terstappen LW: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 21:1111–1117. 2002.PubMed/NCBI
28	Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, et al: Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res. 14:2673–2680. 2008. View Article : Google Scholar : PubMed/NCBI
29	McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, et al: Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul. 48:113–135. 2008. View Article : Google Scholar : PubMed/NCBI
30	Droog M, Beelen K, Linn S and Zwart W: Tamoxifen resistance: From bench to bedside. Eur J Pharmacol. 717:47–57. 2013. View Article : Google Scholar : PubMed/NCBI
31	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
32	McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Arch Pathol Lab Med. 109:716–721. 1985.PubMed/NCBI
33	Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E and Gazzaniga P: Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 130:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
34	Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V and Theodoropoulos PA: Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC Cancer. 15:3992015. View Article : Google Scholar : PubMed/NCBI
35	Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, et al: In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res. 18:302016. View Article : Google Scholar : PubMed/NCBI
36	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
37	Luo M, Brooks M and Wicha MS: Epithelial-mesenchymal plasticity of breast cancer stem cells: Implications for metastasis and therapeutic resistance. Curr Pharm Des. 21:1301–1310. 2015. View Article : Google Scholar : PubMed/NCBI
38	Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339:580–581. 2013. View Article : Google Scholar : PubMed/NCBI
39	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
40	Mego M, Cierna Z, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Sieberova G, Gronesova P, Manasova D, et al: Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. BMC Cancer. 15:5332015. View Article : Google Scholar : PubMed/NCBI
41	Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J and Scaltriti M: AKT signaling in ERBB2-amplified breast cancer. Pharmacol Ther. 158:63–70. 2016. View Article : Google Scholar : PubMed/NCBI
42	Nahta R: Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem. 19:1065–1075. 2012. View Article : Google Scholar : PubMed/NCBI
43	Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB and Muller WJ: Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 69:5057–5064. 2009. View Article : Google Scholar : PubMed/NCBI
44	Wickenden JA and Watson CJ: Key signaling nodes in mammary gland development and cancer. Signalling downstream of PI3Kinase in mammary epithelium: A play in 3 Akts. Breast Cancer Res. 12:2022010. View Article : Google Scholar : PubMed/NCBI
45	Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, et al: Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 15:7266–7276. 2009. View Article : Google Scholar : PubMed/NCBI
46	Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008. View Article : Google Scholar : PubMed/NCBI
47	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
48	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
49	Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2 and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65:2554–2559. 2005. View Article : Google Scholar : PubMed/NCBI
50	https://www.mycancergenome.org/content/disease/breast-cancer/pik3caAccessed. January 18–2017.
51	Karakas B, Bachman KE and Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
52	Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D and Marchetti A: PIK3CA mutation and histological type in breast carcinoma: High frequency of mutations in lobular carcinoma. J Pathol. 208:350–355. 2006. View Article : Google Scholar : PubMed/NCBI
53	Bachmann KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al: The PIK3CA gene is mutated with high frequency in human cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
54	Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI
55	Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
56	Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, et al: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7:R609–R616. 2005. View Article : Google Scholar : PubMed/NCBI
57	Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
58	Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI
59	Tomita H, Tanaka K, Tanaka T and Hara A: Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 7:11018–11032. 2016.PubMed/NCBI
60	Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, et al: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 16:45–55. 2010. View Article : Google Scholar : PubMed/NCBI
61	Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D and Georgoulias V: Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res. 10:R802008. View Article : Google Scholar : PubMed/NCBI
62	Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, O'Brien C, Patel R, Sumiyoshi T, Fu L, et al: Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One. 9:e884012014. View Article : Google Scholar : PubMed/NCBI
63	Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, et al: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 10:1093–1101. 2011. View Article : Google Scholar : PubMed/NCBI
64	Kalinsky K, Heguy A, Bhanot UK, Patil S and Moynahan ME: PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat. 129:635–643. 2011. View Article : Google Scholar : PubMed/NCBI
65	Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL and van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA. 100:15901–15905. 2003. View Article : Google Scholar : PubMed/NCBI
66	Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, Davis RW and Jeffrey SS: Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 14:4562014. View Article : Google Scholar : PubMed/NCBI
67	Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V and Lianidou E: PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res. 20:5823–5834. 2014. View Article : Google Scholar : PubMed/NCBI
68	Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli E and Nagai MA: PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo). 67:1285–1290. 2012. View Article : Google Scholar : PubMed/NCBI
69	Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 107:10208–10213. 2010. View Article : Google Scholar : PubMed/NCBI
70	Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
71	Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 100:1062–1068. 2009. View Article : Google Scholar : PubMed/NCBI
72	Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, et al: Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2:78–91. 2013. View Article : Google Scholar : PubMed/NCBI
73	Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1 in breast cancer: A story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar : PubMed/NCBI
74	Zhong Y, Lin Y, Shen S, Zhou Y, Mao F, Guan J and Sun Q: Expression of ALDH1 in breast invasive ductal carcinoma: An independent predictor of early tumor relapse. Cancer Cell Int. 13:602013. View Article : Google Scholar : PubMed/NCBI
75	Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y and Sun Q: ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24-phenotype. Med Oncol. 31:8642014. View Article : Google Scholar : PubMed/NCBI
76	Zardavas D, Marvelde LT, Milne R, Joensuu H, Moynahan ME, Hennessy B, Bieche I, Saal LH, Stal O, Iacopetta B, et al: Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients with early-stage breast cancer (BC). ASCO Annual Meeting. 2015.
77	Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, et al: Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 32:1202–1209. 2014. View Article : Google Scholar : PubMed/NCBI
78	Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL and Troxell ML: Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat. 120:409–418. 2010. View Article : Google Scholar : PubMed/NCBI
79	Gil Ciruelos EM: Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
80	Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001. View Article : Google Scholar : PubMed/NCBI
81	Ackermann TF, Hörtnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F, Hellweg R and Lang UE: Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem. 22:735–744. 2008. View Article : Google Scholar : PubMed/NCBI
82	Kalkman HO: The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther. 110:117–134. 2006. View Article : Google Scholar : PubMed/NCBI
83	Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al: Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 30:282–290. 2012. View Article : Google Scholar : PubMed/NCBI
84	PI3K Inhibitor Improves PFS in BELLE-2 trial. Cancer Discov. 6:115–116. 2016. View Article : Google Scholar
85	Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R and Kasimir-Bauer S: Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget. 7:41677–41690. 2016.PubMed/NCBI